Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Reliability of the 6-minute walking test smartphone application.

Journal of neurosurgery. Spine

Stienen MN, Gautschi OP, Staartjes VE, Maldaner N, Sosnova M, Ho AL, Veeravagu A, Desai A, Zygourakis CC, Park J, Regli L, Ratliff JK.
PMID: 31518975
J Neurosurg Spine. 2019 Sep 13;1-8. doi: 10.3171/2019.6.SPINE19559. Epub 2019 Sep 13.

OBJECTIVE: Objective functional measures such as the 6-minute walking test (6WT) are increasingly applied to evaluate patients with degenerative diseases of the lumbar spine before and after (surgical) treatment. However, the traditional 6WT is cumbersome to apply, as it...

Cite
Stienen MN, Gautschi OP, Staartjes VE, et al. Reliability of the 6-minute walking test smartphone application. J Neurosurg Spine. 2019;1-8doi: 10.3171/2019.6.SPINE19559.
Stienen, M. N., Gautschi, O. P., Staartjes, V. E., Maldaner, N., Sosnova, M., Ho, A. L., Veeravagu, A., Desai, A., Zygourakis, C. C., Park, J., Regli, L., & Ratliff, J. K. (2019). Reliability of the 6-minute walking test smartphone application. Journal of neurosurgery. Spine, 1-8. https://doi.org/10.3171/2019.6.SPINE19559
Stienen, Martin N, et al. "Reliability of the 6-minute walking test smartphone application." Journal of neurosurgery. Spine vol. (2019): 1-8. doi: https://doi.org/10.3171/2019.6.SPINE19559
Stienen MN, Gautschi OP, Staartjes VE, Maldaner N, Sosnova M, Ho AL, Veeravagu A, Desai A, Zygourakis CC, Park J, Regli L, Ratliff JK. Reliability of the 6-minute walking test smartphone application. J Neurosurg Spine. 2019 Sep 13;1-8. doi: 10.3171/2019.6.SPINE19559. Epub 2019 Sep 13. PMID: 31518975.
Copy Download .nbib Format: NLM
Digital transformation in spine research and outcome assessment.

The spine journal : official journal of the North American Spine Society

Maldaner N, Tomkins-Lane C, Desai A, Zygourakis CC, Weyerbrock A, Gautschi OP, Stienen MN.
PMID: 32000961
Spine J. 2020 Feb;20(2):310-311. doi: 10.1016/j.spinee.2019.06.027.

No abstract available.

Cite
Maldaner N, Tomkins-Lane C, Desai A, et al. Digital transformation in spine research and outcome assessment. Spine J. 2020;20(2):310-311doi: 10.1016/j.spinee.2019.06.027.
Maldaner, N., Tomkins-Lane, C., Desai, A., Zygourakis, C. C., Weyerbrock, A., Gautschi, O. P., & Stienen, M. N. (2020). Digital transformation in spine research and outcome assessment. The spine journal : official journal of the North American Spine Society, 20(2), 310-311. https://doi.org/10.1016/j.spinee.2019.06.027
Maldaner, Nicolai, et al. "Digital transformation in spine research and outcome assessment." The spine journal : official journal of the North American Spine Society vol. 20,2 (2020): 310-311. doi: https://doi.org/10.1016/j.spinee.2019.06.027
Maldaner N, Tomkins-Lane C, Desai A, Zygourakis CC, Weyerbrock A, Gautschi OP, Stienen MN. Digital transformation in spine research and outcome assessment. Spine J. 2020 Feb;20(2):310-311. doi: 10.1016/j.spinee.2019.06.027. PMID: 32000961.
Copy Download .nbib Format: NLM
Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate.

Frontiers in physiology

Ruiz A, Gautschi I, Schild L, Bonny O.
PMID: 29967582
Front Physiol. 2018 Jun 18;9:476. doi: 10.3389/fphys.2018.00476. eCollection 2018.

SLC2A9 or Glut9 is a voltage sensitive urate transporter, mainly expressed in the kidneys, the liver, and the intestine. Human Glut9 loss-of-function mutations were identified in familial hypouricemia, and several single nucleotide polymorphisms (SNPs) were associated with lower serum...

Cite
Ruiz A, Gautschi I, Schild L, et al. Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate. Front Physiol. 2018;9:476doi: 10.3389/fphys.2018.00476.
Ruiz, A., Gautschi, I., Schild, L., & Bonny, O. (2018). Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate. Frontiers in physiology, 9476. https://doi.org/10.3389/fphys.2018.00476
Ruiz, Anne, et al. "Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate." Frontiers in physiology vol. 9 (2018): 476. doi: https://doi.org/10.3389/fphys.2018.00476
Ruiz A, Gautschi I, Schild L, Bonny O. Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate. Front Physiol. 2018 Jun 18;9:476. doi: 10.3389/fphys.2018.00476. eCollection 2018. PMID: 29967582; PMCID: PMC6016318.
Copy Download .nbib Format: NLM
Effect of oxygen therapy on exercise performance in patients with cyanotic congenital heart disease: Randomized-controlled trial.

International journal of cardiology

Saxer S, Calendo LR, Lichtblau M, Carta A, Müller J, Gautschi F, Berlier C, Furian M, Schwarz EI, Bloch KE, Greutmann M, Ulrich S.
PMID: 34856290
Int J Cardiol. 2022 Feb 01;348:65-72. doi: 10.1016/j.ijcard.2021.11.066. Epub 2021 Nov 30.

BACKGROUND: Patients with unrepaired cyanotic congenital heart disease (CHD) suffer from aggravated hypoxemia during exercise. We tested the hypothesis that supplemental oxygen improves exercise performance in these patients.METHODS: In this randomized, sham-controlled, single-blind, cross-over trial cyanotic CHD-patients underwent four...

Cite
Saxer S, Calendo LR, Lichtblau M, et al. Effect of oxygen therapy on exercise performance in patients with cyanotic congenital heart disease: Randomized-controlled trial. Int J Cardiol. 2021;348:65-72doi: 10.1016/j.ijcard.2021.11.066.
Saxer, S., Calendo, L. R., Lichtblau, M., Carta, A., Müller, J., Gautschi, F., Berlier, C., Furian, M., Schwarz, E. I., Bloch, K. E., Greutmann, M., & Ulrich, S. (2022). Effect of oxygen therapy on exercise performance in patients with cyanotic congenital heart disease: Randomized-controlled trial. International journal of cardiology, 34865-72. https://doi.org/10.1016/j.ijcard.2021.11.066
Saxer, Stéphanie, et al. "Effect of oxygen therapy on exercise performance in patients with cyanotic congenital heart disease: Randomized-controlled trial." International journal of cardiology vol. 348 (2022): 65-72. doi: https://doi.org/10.1016/j.ijcard.2021.11.066
Saxer S, Calendo LR, Lichtblau M, Carta A, Müller J, Gautschi F, Berlier C, Furian M, Schwarz EI, Bloch KE, Greutmann M, Ulrich S. Effect of oxygen therapy on exercise performance in patients with cyanotic congenital heart disease: Randomized-controlled trial. Int J Cardiol. 2022 Feb 01;348:65-72. doi: 10.1016/j.ijcard.2021.11.066. Epub 2021 Nov 30. PMID: 34856290.
Copy Download .nbib Format: NLM
Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension.

Frontiers in medicine

Corbach N, Berlier C, Lichtblau M, Schwarz EI, Gautschi F, Groth A, Schüpbach R, Krähenmann F, Saxer S, Ulrich S.
PMID: 34291063
Front Med (Lausanne). 2021 Jul 05;8:689764. doi: 10.3389/fmed.2021.689764. eCollection 2021.

No abstract available.

Cite
Corbach N, Berlier C, Lichtblau M, et al. Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. Front Med (Lausanne). 2021;8:689764doi: 10.3389/fmed.2021.689764.
Corbach, N., Berlier, C., Lichtblau, M., Schwarz, E. I., Gautschi, F., Groth, A., Schüpbach, R., Krähenmann, F., Saxer, S., & Ulrich, S. (2021). Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. Frontiers in medicine, 8689764. https://doi.org/10.3389/fmed.2021.689764
Corbach, Nadine, et al. "Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension." Frontiers in medicine vol. 8 (2021): 689764. doi: https://doi.org/10.3389/fmed.2021.689764
Corbach N, Berlier C, Lichtblau M, Schwarz EI, Gautschi F, Groth A, Schüpbach R, Krähenmann F, Saxer S, Ulrich S. Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. Front Med (Lausanne). 2021 Jul 05;8:689764. doi: 10.3389/fmed.2021.689764. eCollection 2021. PMID: 34291063; PMCID: PMC8287120.
Copy Download .nbib Format: NLM
Intracranial Efficacy of Selpercatinib in .

Clinical cancer research : an official journal of the American Association for Cancer Research

Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A.
PMID: 34088726
Clin Cancer Res. 2021 Aug 01;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 04.

PURPOSE: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for PATIENTS AND METHODS: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RESULTS: Eighty patients with NSCLC...

Cite
Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial Efficacy of Selpercatinib in . Clin Cancer Res. 2021;27(15):4160-4167doi: 10.1158/1078-0432.CCR-21-0800.
Subbiah, V., Gainor, J. F., Oxnard, G. R., Tan, D. S. W., Owen, D. H., Cho, B. C., Loong, H. H., McCoach, C. E., Weiss, J., Kim, Y. J., Bazhenova, L., Park, K., Daga, H., Besse, B., Gautschi, O., Rolfo, C., Zhu, E. Y., Kherani, J. F., Huang, X., Kang, S., & Drilon, A. (2021). Intracranial Efficacy of Selpercatinib in . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4160-4167. https://doi.org/10.1158/1078-0432.CCR-21-0800
Subbiah, Vivek, et al. "Intracranial Efficacy of Selpercatinib in ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4160-4167. doi: https://doi.org/10.1158/1078-0432.CCR-21-0800
Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in . Clin Cancer Res. 2021 Aug 01;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 04. PMID: 34088726; PMCID: PMC8447251.
Copy Download .nbib Format: NLM
Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.

Journal of inherited metabolic disease

Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Harmatz P, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Andreasen AK, Geist MA, Havnsøe Torp Petersen N, Ingemann L, Hansen T, Blaettler T, Kirkegaard T, Í Dali C.
PMID: 34418116
J Inherit Metab Dis. 2021 Nov;44(6):1463-1480. doi: 10.1002/jimd.12428. Epub 2021 Sep 07.

Niemann-Pick disease type C (NPC) is a rare, genetic, progressive neurodegenerative disorder with high unmet medical need. We investigated the safety and efficacy of arimoclomol, which amplifies the heat shock response to target NPC protein misfolding and improve lysosomal...

Cite
Mengel E, Patterson MC, Da Riol RM, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis. 2021;44(6):1463-1480doi: 10.1002/jimd.12428.
Mengel, E., Patterson, M. C., Da Riol, R. M., Del Toro, M., Deodato, F., Gautschi, M., Grunewald, S., Grønborg, S., Harmatz, P., Héron, B., Maier, E. M., Roubertie, A., Santra, S., Tylki-Szymanska, A., Day, S., Andreasen, A. K., Geist, M. A., Havnsøe Torp Petersen, N., Ingemann, L., Hansen, T., Blaettler, T., Kirkegaard, T., & Í Dali, C. (2021). Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. Journal of inherited metabolic disease, 44(6), 1463-1480. https://doi.org/10.1002/jimd.12428
Mengel, Eugen, et al. "Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment." Journal of inherited metabolic disease vol. 44,6 (2021): 1463-1480. doi: https://doi.org/10.1002/jimd.12428
Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Harmatz P, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Andreasen AK, Geist MA, Havnsøe Torp Petersen N, Ingemann L, Hansen T, Blaettler T, Kirkegaard T, Í Dali C. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis. 2021 Nov;44(6):1463-1480. doi: 10.1002/jimd.12428. Epub 2021 Sep 07. PMID: 34418116.
Copy Download .nbib Format: NLM
Structural and Functional Analysis of Gly212 Mutants Reveals the Importance of Intersubunit Interactions in ASIC1a Channel Function.

Frontiers in molecular biosciences

Bignucolo O, Vullo S, Ambrosio N, Gautschi I, Kellenberger S.
PMID: 32411719
Front Mol Biosci. 2020 Apr 28;7:58. doi: 10.3389/fmolb.2020.00058. eCollection 2020.

Acid-sensing ion channels (ASICs) act as pH sensors in neurons. ASICs contribute to pain sensation, learning, fear behavior and to neuronal death after ischemic stroke. Extracellular acidification induces a transient activation and subsequent desensitization of these Na

Cite
Bignucolo O, Vullo S, Ambrosio N, et al. Structural and Functional Analysis of Gly212 Mutants Reveals the Importance of Intersubunit Interactions in ASIC1a Channel Function. Front Mol Biosci. 2020;7:58doi: 10.3389/fmolb.2020.00058.
Bignucolo, O., Vullo, S., Ambrosio, N., Gautschi, I., & Kellenberger, S. (2020). Structural and Functional Analysis of Gly212 Mutants Reveals the Importance of Intersubunit Interactions in ASIC1a Channel Function. Frontiers in molecular biosciences, 758. https://doi.org/10.3389/fmolb.2020.00058
Bignucolo, Olivier, et al. "Structural and Functional Analysis of Gly212 Mutants Reveals the Importance of Intersubunit Interactions in ASIC1a Channel Function." Frontiers in molecular biosciences vol. 7 (2020): 58. doi: https://doi.org/10.3389/fmolb.2020.00058
Bignucolo O, Vullo S, Ambrosio N, Gautschi I, Kellenberger S. Structural and Functional Analysis of Gly212 Mutants Reveals the Importance of Intersubunit Interactions in ASIC1a Channel Function. Front Mol Biosci. 2020 Apr 28;7:58. doi: 10.3389/fmolb.2020.00058. eCollection 2020. PMID: 32411719; PMCID: PMC7198790.
Copy Download .nbib Format: NLM
Smartphone-Based Self-Assessment of Objective Functional Impairment (6-Minute Walking Test) in Patients Undergoing Epidural Steroid Injection.

Neurospine

Zeitlberger AM, Sosnova M, Ziga M, Steinsiepe V, Gautschi OP, Stienen MN, Maldaner N.
PMID: 32252164
Neurospine. 2020 Mar;17(1):136-142. doi: 10.14245/ns.2040022.011. Epub 2020 Mar 31.

Epidural steroid injection (ESI) represents a popular treatment option in patients with lumbar degenerative disc disease (DDD). The main objective of the article was to determine whether the 6-minute walking test (6WT) could assist in the discrimination between ESI...

Cite
Zeitlberger AM, Sosnova M, Ziga M, et al. Smartphone-Based Self-Assessment of Objective Functional Impairment (6-Minute Walking Test) in Patients Undergoing Epidural Steroid Injection. Neurospine. 2020;17(1):136-142doi: 10.14245/ns.2040022.011.
Zeitlberger, A. M., Sosnova, M., Ziga, M., Steinsiepe, V., Gautschi, O. P., Stienen, M. N., & Maldaner, N. (2020). Smartphone-Based Self-Assessment of Objective Functional Impairment (6-Minute Walking Test) in Patients Undergoing Epidural Steroid Injection. Neurospine, 17(1), 136-142. https://doi.org/10.14245/ns.2040022.011
Zeitlberger, Anna Maria, et al. "Smartphone-Based Self-Assessment of Objective Functional Impairment (6-Minute Walking Test) in Patients Undergoing Epidural Steroid Injection." Neurospine vol. 17,1 (2020): 136-142. doi: https://doi.org/10.14245/ns.2040022.011
Zeitlberger AM, Sosnova M, Ziga M, Steinsiepe V, Gautschi OP, Stienen MN, Maldaner N. Smartphone-Based Self-Assessment of Objective Functional Impairment (6-Minute Walking Test) in Patients Undergoing Epidural Steroid Injection. Neurospine. 2020 Mar;17(1):136-142. doi: 10.14245/ns.2040022.011. Epub 2020 Mar 31. PMID: 32252164; PMCID: PMC7136089.
Copy Download .nbib Format: NLM
Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia.

JIMD reports

Welling L, Waisbren SE, Antshel KM, Colhoun HO, Gautschi M, Grünewald S, Holman R, van der Lee JH, Treacy EP, Bosch AM.
PMID: 28391442
JIMD Rep. 2017;37:115-123. doi: 10.1007/8904_2017_22. Epub 2017 Apr 09.

INTRODUCTION: Cognitive impairment is a well-known complication of classical galactosemia (CG). Differences in patient characteristics and test methods have hampered final conclusions regarding the extent of intellectual disabilities in CG. The primary aim of this systematic review was to...

Cite
Welling L, Waisbren SE, Antshel KM, et al. Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia. JIMD Rep. 2017;37:115-123doi: 10.1007/8904_2017_22.
Welling, L., Waisbren, S. E., Antshel, K. M., Colhoun, H. O., Gautschi, M., Grünewald, S., Holman, R., van der Lee, J. H., Treacy, E. P., & Bosch, A. M. (2017). Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia. JIMD reports, 37115-123. https://doi.org/10.1007/8904_2017_22
Welling, Lindsey, et al. "Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia." JIMD reports vol. 37 (2017): 115-123. doi: https://doi.org/10.1007/8904_2017_22
Welling L, Waisbren SE, Antshel KM, Colhoun HO, Gautschi M, Grünewald S, Holman R, van der Lee JH, Treacy EP, Bosch AM. Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia. JIMD Rep. 2017;37:115-123. doi: 10.1007/8904_2017_22. Epub 2017 Apr 09. PMID: 28391442; PMCID: PMC5740047.
Copy Download .nbib Format: NLM
External Validation of the Minimum Clinically Important Difference in the Timed-Up-and-Go (TUG) Test after Surgery for Lumbar Degenerative Disc Disease.

Spine

Maldaner N, Sosnova M, Ziga M, Zeitlberger AM, Bozinov O, Gautschi OP, Weyerbrock A, Regli L, Stienen MN.
PMID: 34033596
Spine (Phila Pa 1976). 2021 May 24; doi: 10.1097/BRS.0000000000004128. Epub 2021 May 24.

STUDY DESIGN: Prospective observational cohort study.OBJECTIVE: To provide external validation of the minimum clinically important difference (MCID) of the Timed-Up-and-Go (TUG) test.SUMMARY OF BACKGROUND DATA: The TUG test is one of the best explored and most frequently applied objective...

Cite
Maldaner N, Sosnova M, Ziga M, et al. External Validation of the Minimum Clinically Important Difference in the Timed-Up-and-Go (TUG) Test after Surgery for Lumbar Degenerative Disc Disease. Spine (Phila Pa 1976). 2021;doi: 10.1097/BRS.0000000000004128.
Maldaner, N., Sosnova, M., Ziga, M., Zeitlberger, A. M., Bozinov, O., Gautschi, O. P., Weyerbrock, A., Regli, L., & Stienen, M. N. (2021). External Validation of the Minimum Clinically Important Difference in the Timed-Up-and-Go (TUG) Test after Surgery for Lumbar Degenerative Disc Disease. Spine, . https://doi.org/10.1097/BRS.0000000000004128
Maldaner, Nicolai, et al. "External Validation of the Minimum Clinically Important Difference in the Timed-Up-and-Go (TUG) Test after Surgery for Lumbar Degenerative Disc Disease." Spine vol. (2021). doi: https://doi.org/10.1097/BRS.0000000000004128
Maldaner N, Sosnova M, Ziga M, Zeitlberger AM, Bozinov O, Gautschi OP, Weyerbrock A, Regli L, Stienen MN. External Validation of the Minimum Clinically Important Difference in the Timed-Up-and-Go (TUG) Test after Surgery for Lumbar Degenerative Disc Disease. Spine (Phila Pa 1976). 2021 May 24; doi: 10.1097/BRS.0000000000004128. Epub 2021 May 24. PMID: 34033596.
Copy Download .nbib Format: NLM
Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders.

Journal of neurosurgery. Spine

Maldaner N, Sosnova M, Zeitlberger AM, Ziga M, Gautschi OP, Regli L, Bozinov O, Weyerbrock A, Stienen MN.
PMID: 33974372
J Neurosurg Spine. 2021 May 07; doi: 10.3171/2020.11.SPINE201621. Epub 2021 May 07.

OBJECTIVE: The 6-minute walking test (6WT) and the Timed Up and Go (TUG) test are two of the most commonly applied standardized measures of objective functional impairment that help support clinical decision-making for patients undergoing surgery for degenerative lumbar...

Cite
Maldaner N, Sosnova M, Zeitlberger AM, et al. Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders. J Neurosurg Spine. 2021;doi: 10.3171/2020.11.SPINE201621.
Maldaner, N., Sosnova, M., Zeitlberger, A. M., Ziga, M., Gautschi, O. P., Regli, L., Bozinov, O., Weyerbrock, A., & Stienen, M. N. (2021). Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders. Journal of neurosurgery. Spine, . https://doi.org/10.3171/2020.11.SPINE201621
Maldaner, Nicolai, et al. "Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders." Journal of neurosurgery. Spine vol. (2021). doi: https://doi.org/10.3171/2020.11.SPINE201621
Maldaner N, Sosnova M, Zeitlberger AM, Ziga M, Gautschi OP, Regli L, Bozinov O, Weyerbrock A, Stienen MN. Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders. J Neurosurg Spine. 2021 May 07; doi: 10.3171/2020.11.SPINE201621. Epub 2021 May 07. PMID: 33974372.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries